Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E–Mutated Advanced Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
Eur. J. Cancer 2022 Jan 21;163(xx)152-162, Z Wang, BD Qin, CY Ye, MM Wang, LY Yuan, WP Dai, L Sun, K Liu, WX Qin, XD Jiao, XN Li, YS ZangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.